Obesity, Insulin Resistance, and Metabolic Syndrome: A Study in WNIN/Ob Rats from a Pancreatic Perspective

Vijayalakshmi Venkatesan, Soundarya L. Madhira, Venkata M. Malakapalli, Maniprabha Chalasani, Sarfaraz N. Shaik, Vasudevan Seshadri, Venkaiah Kodavalla, Ramesh R. Bhonde, and Giridharan Nappanveetil

1 Department of Biochemistry/Stem Cell Research, National Institute of Nutrition, Indian Council of Medical Research, Jamai-Osmania (P.O), Hyderabad, Andhra Pradesh 500007, India
2 Laboratory 12, National Center for Cell Sciences, NCCS Complex, Pune University Campus, Ganeshkhind, Pune, Maharashtra 411007, India
3 Division of Community Studies, National Institute of Nutrition, Hyderabad, Andhra Pradesh 500007, India
4 Manipal Institute of Regenerative Medicine, GKV Post, Bellary Road, Allalasandra, Yelahanka, Bangalore, Karnataka 560065, India
5 National Center for Laboratory Animal Sciences, National Institute of Nutrition, Hyderabad, Andhra Pradesh 500007, India

Correspondence should be addressed to Vijayalakshmi Venkatesan; v.venkateshan@gmail.com

Received 16 July 2013; Revised 9 November 2013; Accepted 11 November 2013

Academic Editor: Oreste Gualillo

Copyright © 2013 Vijayalakshmi Venkatesan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alterations in pancreatic milieu to adapt to physiological shifts occurring in conditions of obesity and metabolic syndrome (MS) have been documented, though mechanisms leading to such a state have remained elusive so far. The data presented here tries to look at the gravity of metabolic insult during the early and prolonged phases of obesity/insulin resistance (IR) depicted in WNIN/Ob strain of rats—an obese euglycemic mutant rat model developed indigenously at our institute which is highly vulnerable for a variety of degenerative diseases. The present results in situ show the participation of several confounding factors in the pancreatic milieu that collectively coprecipitates for a state of profound inflammation in the pancreas (among Mutant compared to Lean/Control) which gets worsened with age. These include hypertrophy, macrophage infiltration (CD11b/TNFα/IL6), apoptosis, β-cell vacuolation, hyperinsulinemia (HI), and stress markers (RL-77/HSP104/TBARS) all of which correlated well with indices for obesity (2-3 fold), IR (1.5-3 fold), and HI (2-3 fold). Further, supportive data was also obtained from in vitro studies using islet cell cultures amongst phenotypes. Taken together, these results advocate that inflammation was the major precipitating factor to cause islet cell dysfunctions (in situ and in vitro) in these Mutant rats compared to their Lean littermates and parental Control.

1. Introduction

Obesity with insulin resistance (IR) forms a major part of metabolic syndrome (MS) and its co-precipitation with etiological factors has been shown to cause dysregulation of several dynamic processes, thereby predisposing the organism to long-term micro- and macro-vascular complications [1]. Interestingly, animal models (ob/ob and db/db mice and Zucker and Koletsky rats) have greatly helped our understanding of the pathophysiology associated with MS, although the mechanism(s) remain(s) obscure [2]. WNIN/Ob rat strain (Mutant) is a new entrant to the list of obese animal models and is derived indigenously from the Wistar rat strain of our institute (WNIN), maintained at our institute in an inbred status since 1920. WNIN/Ob, which arose spontaneously from WNIN in 1997, is euglycemic and portrays features of obesity/IR with distinct clinical and biochemical features like hyperinsulinemia (HI), hypertriglyceridemia, and hypercholesterolemia along with hyperphagia, polydipsia, polyuria, and proteinuria akin to other obese model systems [3]. Interestingly, this is the biggest obese rat strain (1.4 Kgs) so far recorded in literature, and is leptin resistant with unaltered leptin or its receptor coding sequences and the strain exhibits three distinct phenotypes:
homozygous lean (+/+), heterozygous carrier (+/−), and homozygous obese (−/−), in a typical Mendelian ratio of 1:2:1. The mode of inheritance is autosomal incomplete dominance. Attempts to localize the mutation in this model system are in progress and a recent study from our institute has localized the observed unilocus mutation to exist in a 4.3 cM region with flanking markers D5Rat256 and D5Wox37 on chromosome 5 upstream of the leptin receptor [4]. These Mutants stand apart from other similar models, due to the presence of “kinky tail” in heterozygous carriers (+/−) and in homozygous obese (−/−) phenotypes. Apart from obesity, these Mutants show a variety of degenerative diseases, as they cross one year, like breast tumors and lipomas, cataract and retinal degenerations (in 20%), hypertension [5], osteoporosis, polycystic ovaries, kidney damage, impaired immunity, and accelerated aging with the life span of Mutants reduced to 1.5 years, while a normal rat lives up to 3–3.5 years [6].

The impetus obtained from our published data using adipose tissue (AT) [7] and bone marrow derived mesenchymal stem cells (BM-MSCs) [8] from these animals supported an in situ inflammation with obesity as a predominant metabolic lesion. The metabolic interrelationships and crosstalks (cytokines) contributed from skeletal muscle (SM) and AT have been shown to be decisive for the maintenance of glucose homeostasis [9] and dysregulations have been shown to influence the β-cell functions and integrity [10]. It is to be noted here that β-cells of the pancreas have an inherent weak antioxidant system as compared to any organ [11] and with persistent IR [3], hyperglycemia, and obesity or HI could predispose the organism to long-term secondary complications [12,13] vis-à-vis β-cell dysfunctions [12].

We hypothesize that WNIN/Ob rats (Mutants) with their inherent phenotypic features would form an ideal model to assess the gravity of metabolic insult both at early and prolonged (chronic) phases seen with age (1, 6, and 12 months). In the present study we have compared homozygous obese rats (WNIN/Ob (−/−)) (Mutants) with their age matched homozygous lean (WNIN/Ob (+/+)) littermates (Leans) and parental (WNIN) controls (Controls) for all the parameters (islet cell architecture, inflammation, and islet cell functions) studied in in situ (tissue) and in vitro (primary islet cell cultures). This is primarily to understand the early and chronic phases of the metabolic insult which has been reported with these Mutants and is appreciable with age (1, 6, and 12 months).

2. Material and Methods

2.1. Animals. Experimental procedures were in compliance with the principles of laboratory animal care and approved by the Institutional Ethical Committee on Animal Experiments, Hyderabad, India. Male rats, six per strain, (Mutant, Lean, and Control) matched for age (1, 6, and 12 months) were obtained from an inbred colony of the National Centre for Laboratory Animal Sciences (NCLAS) facility at our institute. To understand the effect of accelerated aging on the pathophysiology of MS in the 12-month Mutant rats, we have made a comparison of 12-month Mutants with two-year-old (24-month) Control rats in few critical metabolic parameters. The animals were given normal rat chow with water ad libitum. They were maintained under optimal conditions of 12 hr light/dark cycles, with temperature (20 ± 2°C) with relative humidity (50 ± 10%) kept constant. Prior to the day of euthanization, animals were fasted overnight to normalize any differences in feeding patterns and to minimize experimental variations.

2.2. Physiological Parameters. Anthropometric measurements (body/pancreatic tissue weights), blood glucose [7], insulin (plasma/tissue) [11, 14] and IR indices—Homeostasis Model of Assessment for Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI) were measured as described previously [8]. Thiobarbituric acid reacting species (TBARS), a marker of global oxidative stress/lipid peroxidation, were measured in plasma/pancreatic tissue as per our earlier protocol [15].

2.3. Tissue Morphometry. Pancreatic tissues (formalin fixed and paraffin embedded) of 6–8μm thickness were processed for hematoxylin and eosin (H&E), and immunofluorescence including TUNEL assay [7, 16, 17]. H&E stained sections were used for studying islet morphology (islet size, β-cell vacuolation, and AT/macrophage infiltration), and images were captured using an inverted microscope (TE2000S, Nikon, Japan) with ACT2U software (version 1.7, Nikon, Japan).

2.4. Immunofluorescence. Immunostaining of the pancreatic sections was performed as described previously [8,16]. In brief, pancreatic sections were blocked with 4% horse serum and incubated overnight at 4°C using either 1:100 dilution of primary antibodies for mouse antihuman insulin (Sigma, USA), rabbit antihuman glucagon (Santa Cruz, USA), goat antihuman PDX-1 (Santa Cruz, USA), rabbit polyclonal antihuman HSP104 (gift), mouse polyclonal anti-RL-77 (gift, National Centre for Cell Sciences, Pune, India), or 1:400 dilution of rabbit polyclonal anti-IL-6 (Abcam, USA). After repeated washes, the sections were incubated with secondary antibodies (1:200 dilution) for anti-mouse FITC (Insulin/RL-77), anti-rabbit Texas Red (glucagon) (Santa Cruz, USA), anti-goat Texas Red (Pdx-1), anti-rabbit Cy3 (HSP104) (Jackson’s Laboratories, USA), and anti-rabbit Alexa 568 (IL-6). After several more washes the sections were mounted using DAPI (Vectashield, Vector Laboratories, USA). Antigen retrieval for the nuclear transcription factor Pdx-1 was performed by treating tissue sections with 2N HCl for 1 hr at room temperature. Similarly, dual fluorescence for CD11b and TNFα was carried out using FITC conjugated mouse anti-rat CD11b (BD Biosciences, USA) and PE hamster anti-rat TNFα (BD Biosciences, USA) at 1:100 dilution. Immunostaining of pancreatic sections of 24-month-old WNIN rats was performed for insulin, glucagon, CD11b, TNFα, IL-6, and Pdx-1 as described above. The images were captured using 405 (DAPI), 488 (FITC), 514 (Cy3), 561
(PE/568), and 594 (Texas red) lasers using a confocal microscope (Leica SP5, Leica Microsystems, Germany) with Leica Advanced Fluorescence (LAF) software (Leica Microsystems, Germany). The fluorescence intensities were calculated as relative fluorescent units (RFU) (relative to isotype control) using the LAF software and represented as RFU per unit area. All images were captured using Leica Advanced Fluorescence software (Mannheim, Germany) in Leica Confocal Microscope SP5 series (Mannheim, Germany) at a magnification of 400x unless otherwise specified. An asterisk (*) indicates a significance of \( P < 0.05 \) by ANOVA compared to Control and (S) represents the statistical significance (\( P < 0.05 \) by ANOVA) compared to the phenotype at 1 month. Values have been represented as Mean ± SE (\( n = 6 \)) from three independent experiments performed in duplicate.

\[ \beta \text{-cell mass was calculated from the insulin stained sections, captured using LAF software as mentioned above [18] at a final magnification of 200x. Area of } \beta \text{-cells was determined by quantifying the cross-sectional area occupied by } \beta \text{-cells to the total cross-sectional area of the tissue (in all multiple fields per slide) and represented as a product of the cross-sectional area of } \beta \text{-cells/total tissue and the weight of the pancreatic tissue before fixation. Total tissue area was corrected for the unstained area inside the fat cells, by tracing the region occupied by fat cells in the H&E stained specimens (at a final magnification of 200x).} \]

### 2.5. TUNEL Assay

Apoptosis was studied using DeadEnd Fluorometric TUNEL assay kit (Promega, USA) as per the manufacturer’s protocol. Apoptotic cells were visualized with FITC positive nuclei and images were captured using 405 and 488 lasers under a confocal microscope using LAF software. TUNEL assay was also performed on 24-month-old Control pancreatic tissue sections. Apoptotic index (AI) was calculated as the ratio of number of TUNEL positive nuclei to the total number of nuclei per islet [19].

### 2.6. Gene Expression Analysis

The methodology for semi-quantitative reverse transcription polymerase chain reaction (sq-RT-PCR) used was similar to the procedures reported earlier by us [8]. Total RNA (from ~100 mg of pancreatic tissue) was isolated using TriReagent (Sigma, USA) and cDNA was prepared from 2 μg of total RNA using enhanced avian myeloblastosis virus reverse transcriptase enzyme (Sigma, USA) and amplified with JumpStart AccuTaq LA DNA Polymerase (Sigma, USA). Primers were designed with the aid of PrimerQuest software (Integrated DNA technologies, Coralville, IA). PCR was carried out to analyze the expression of *Insulin*-I (sense: caatacatagcattacaagct; antisense: ttattatcagcaggggggtt), *Pdx-1* (sense: tataaggcaccgtgctgct; antisense: ttaccttgagcactgtc), and *β-actin* (sense: tggagttggaggtgcag; antisense: ttgtagttggagtccagttc). Amplicons were resolved electrophoretically (1.2% agarose gel), visualized in GelDoc (BioRad, Italy), and quantitated by densitometric analysis using QuantityOne software (BioRad, Italy). Results have been normalized against the housekeeping gene *β-actin*.

Quantitative real-time PCR was performed for each sample in triplicate using a CFX 96 Touch Real-Time PCR system (BioRad, Italy) in a 96-well PCR plate (BioRad, Italy). Each assay (20 μL total volume) contained nuclease-free water (11 μL-12 μL), cDNA template (conc—2 ng/μL), gene-specific primers (conc—4.5 pm/μL), and 5 μL SYBR green PCR Master Mix (KAPA Biosystems, South Africa). The cycling conditions were enzyme activation at 95°C for 30 s; 40 cycles of 95°C for 30 s (denaturation); and *Pdx-1* at 60°C and *Insulin*-1 at 58°C for 30 s (annealing) with a single fluorescence measurement at 72°C for 30 s (dissociation curve). Specificity of the PCR products was confirmed by the melting curve program with temperatures in the range of 60 to 95°C with a heating rate of 0.5 to 0.05°C/s and a continuous fluorescence measurement. Relative differences in gene expression between groups (Mutant, Lean, and Control—aged 1, 6, and 12 months) are represented as fold change using \( 2^{ΔΔCT} \) method as per the protocol of Dussault and Pouliot [20].

### 2.7. In Vitro Assays

**Islet Isolation, Primary Cell Cultures, Viability, and Functional Assays.** Islets were isolated under sterile conditions from all three phenotypes (Mutant, Lean, and Control) as per our published protocol [14]. Keeping in view the fact that Mutants have 47% fat in their body which interferes with the islet integrity and cell yield by forming a viscous jelly-like material when compared to their age matched parental Controls, we had optimized conditions for islet cell isolation with minimal viscous material and maximum islet yield and functional response (primary islet cell cultures) using differential collagenase digestion [14]. Briefly, pancreas were collected under sterile conditions, minced and subjected to collagenase digestion using either 0.5 mg/mL for Mutants or 1 mg/mL for Lean/Control. The digestion mixture also contained 2 mg/mL soy bean trypsin inhibitor (Sigma, USA) and 2% BSA fraction V (Sigma, USA). All steps were performed at optimal temperature (37 ± 1.5°C) and pH (7.0 or 7.7-7.9) [21] and digestion (turbidity appearance) was stopped with the addition of chilled RPMI-1640 containing 10% FCS (1:3 ratio) in order to prevent islet necrosis during isolation [22]. The digests were washed (3x), and islet-cell-enriched fractions were seeded in RPMI-1640 medium with 10% FBS with antibiotics (Invitrogen, USA). After a period of 24–48 hrs, the islets were harvested by handpicking for *in vitro* assays including viability by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay [23] and islet cell integrity by dithizone (DTZ) staining (Sigma, USA) [14], and images were captured with a Nikon inverted microscope using ACT-2U software. Insulin secretion assay was carried out from the primary islet cell cultures of Mutant, Lean, and Control phenotypes at basal (5.5 mmol/L) followed by high glucose (16.5 mmol/L) challenge as described earlier [8, 14]. Similarly, insulin secretion assay to assess islet cell function was also performed from islets (primary islet cell cultures) derived from 24-month-old Control rats [14].
2.8. Ultrastructural Analysis. For ultrastructural studies, the primary islet cell cultures of only 12-month-old animals (Mutant, Lean, and Control) presenting increased degenerative changes [3, 6, 24] were processed for both scanning electron microscopy (SEM) [25] (performed at 5 to 10 KV in S3400N, Hitachi, Japan) and transmission electron microscopy (TEM) [26] (performed at 75 KV in H-600, Hitachi, Japan), respectively.

2.9. Statistics. Descriptive statistics (Mean/SE) were calculated for all the samples using SPSS version 15.0 software and values have been represented as Mean ± SE (n = 6). To compare between the phenotypes, analysis of variance (ANOVA) followed by post hoc tests (LSD/Dunnett's C test) was carried out based on Levene's test for equality of error variances. Bivariate correlation analysis (2-tailed) for better understanding of the correlation between metabolic, anthropometric, and physiological parameters was performed using the same software (SPSS version 15.0) for a better understanding of the correlation between these parameters. P < 0.05 was considered statistically significant for all the measurements. Data have been computed from three independent experiments carried out in duplicate for tissue morphometry, immunofluorescence, PCR, and ultrastructural analyses and from six animals per group for all anthropometric/physiological analyses.

3. Results

3.1. Physiological Parameters

3.1.1. Body Weight/Pancreatic Weight. A significant increase in the body weight of Mutants, which increased with age (1, 6, and 12 months) to a tune of 4–7-fold (P < 0.05) compared to their Leans and Controls, was observed (Figure 1(a)). Similar lines, pancreatic weights were also increased in Mutants by 2-fold when compared to their Leans and Controls at all age groups (Figure 1(b)). However, both body weights and pancreatic weights were almost comparable between Leans and Controls with age (Figures 1(a) and 1(b)).

3.1.2. Glucose and Insulin (Plasma and Tissue Insulin). The animals were euglycemic [6] in all age groups with fasting blood glucose (FBG) in the range of 3.9–6.1 mmoles/L. The plasma and tissue insulin levels were almost similar during the early age, that is, at 1 month, amongst phenotypes, but with age Mutants demonstrated a significant increase in both plasma (HI) and tissue insulin levels being appreciable at 6 months (compared to Leans by 3.03- and 1.10-fold) and Controls (by 3.70- and 2.82-fold) and 12 months (compared to Leans by 5.51- and 1.71-fold) and Controls (by 3.77- and 1.39-fold), respectively (Figures 1(c) and 1(j)). The plasma (2.13 ± 0.52) and tissue insulin (5.36 ± 0.75) levels measured in 24-month-old Control rats were, however, found to be lower than those observed in 12-month Controls.

3.1.3. Oxidative Stress (Malonaldehyde Measurements). TBARS signifying global oxidative stress indices were also upregulated significantly (P < 0.05) in Mutants at all ages which was reflected both in plasma (Figure 1(f)) and pancreatic tissue (Figure 1(k)) levels compared to their Leans and Controls.

3.1.4. Measurement of IR. We observed a significant increase in HOMA-IR (Figure 1(d)) supported by a significant decrease in QUICKI (Figure 1(e)) among Mutants at 6 and 12 months but not at 1 month suggesting an increase in IR with age. However Lean and Control rats remained insulin sensitive as reflected by IR Indices. Based on the HOMA-IR and QUICKI indices calculated 24-month-old Control rats also showed IR (1.21 and 0.32, resp.) as an age dependent effect similar to Mutant rats.

3.2. Morphometric Studies. H&E staining of Mutant pancreatic tissues at 6 and 12 months of age demonstrated a marked hypertrophy with large and irregular islets (Figure 1(g)), β-cell vacuolation (Figure 1(h)), and disruption in the outer collagenous layer as compared to the intact morphology of the islets noted with Leans and Controls (Figures 1(g) and 1(h)). Further, evidence for an increased vasculature, intraislet vacuolation, and fat infiltration into the exocrine region was also predominant in Mutant pancreas when compared to its Lean and Control (Figure 1(g)). However the morphology was more or less similar to the early age group of 1 month studied amongst the phenotypes (Figures 1(g)-(1(h)).

As shown in Figure 1(i), Mutant pancreas showed increase in islet size measured using ACT2U software (Nikon microscope), which was significant among Mutants by 1.25-, 1.54-, and 1.35-fold compared to Leans and by 1.40-, 1.38-, and 1.54-fold compared to their Controls at 1, 6, and 12 months (Figure 1(i)). However, the differences observed in islet size between Leans and Controls were not statistically significant. Islet size among 24-month Controls was found to be 320.45 ± 15.02 μm, in line with the trends expected with 12-month Mutants.

3.3. Immunofluorescence. Immunostaining of pancreatic tissues with insulin and glucagon amongst the phenotypes demonstrated a central core of insulin positive β-cells surrounded by a peripheral mantle of glucagon positive α-cells at all the ages studied (Figures 2(a)–2(d)). As depicted in Figure 2(f), insulin immunopositive cells expressed as RFU per unit (relative to isotype controls (Figure 2(e))) were significantly higher in Mutants at 1, 6, and 12 months compared to Leans (by 1.72-, 3.31-, and 1.27-fold) and Controls (by 2.74-, 3.03-, and 1.42-fold), respectively, substantiating HI/increased tissue insulin levels observed. However, similar levels of insulin positivity (RFU per unit area) were observed among Lean and Control with age (Figures 2(a)–2(d) and 2(f)). Among the 24-month Controls, RFU per unit area for insulin was found to be 30.75 ± 2.6.

Interestingly, glucagon positive cells (RFU per unit area relative to isotype controls (Figure 2(e))) were also increased in Mutant pancreas, both at an early phase, that is, 1 month, (RFU = 19.32) and midphase, that is, 6 months, (RFU = 16.04) unlike at 12 months (RFU = 14.68) which showed a
**Figure 1:** Continued.
decrease. Leans and Controls were almost comparable at all ages (Figures 2(a)–2(d) and 2(g)). However, the levels among 24-month Controls were found to be 10.37 ± 1.6, which was similar to the levels observed among 12-month Mutants.

Further, insulin/glucagon ratio (per se indices) indicating the relative percentage of β-/α-cells was also significant (P < 0.05) at the higher age group (12 months) among Mutant compared to its Lean and Control, further denoting HI decrease which is probably attributed to increased degenerative effects (hypertrophy and apoptosis). Comparison of β-cell mass between Leans and Controls (Figure 2(i)) does show a consistence in tune with the observed islet cell size.

Immunostaining of the pancreatic tissue sections with insulin and PDX-1 demonstrated decreased PDX-1 intensities (RFU per unit area compared to isotype control (Figure 7(e))) (Figures 7(a)–7(f)).

3.3.1. Inflammatory (CD11b, TNFα, and IL-6) and Stress Markers. As shown in Figure 3(a), HSP-104 localization (cytosolic region) in islets was significantly increased in Mutants at all ages (12 months > 6 months > 1 month) when compared to that in Leans and Controls. Although Leans tend to show an increase for HSP-104 (RFU per unit area with reference to isotype control (Figure 3(c))) compared to Controls, this was not statistically significant (Figures 3(a) and 3(d)). On similar lines, Mutant islets also demonstrated increased localization of endoplasmic reticulum (ER) stress protein RL-77 (RFU per unit area with reference to isotype control (Figure 3(e))) compared to Lean and Control (Figures 3(b) and 3(f)).

Figures 4(a)–4(e) depict dual immunofluoresence for CD11b/TNFα (RFU per unit area with reference to isotype control (Figure 4(c))), that is, relative percentage of macrophages/mast cells/inflammatory protein in situ which was significantly upregulated in Mutants with age. However, Leans and Controls showed few immunopositive cells for CD11b/TNFα in comparison to Mutants with age (Figures 4(a)–4(e)). In addition, increased IL-6 immunolocalization with increasing age was seen amongst Mutant pancreatic islets (Figures 4(f)–4(i)).

3.3.2. Apoptosis/TUNEL Assay. Age dependent increase in apoptosis was evident amongst the phenotypes, that is, Mutants, Leans, and Controls, but the quantitative increase in AI was more predominant in Mutants (by 1.20-, 2.84-, and 15.77-fold) compared to that in Leans (by 1.20-, 2.84-, and 15.77-fold) and Controls (by 5.16-, 5.67-, and 9.98-fold) (Figure 5(d)), respectively. Interestingly, apoptotic rate was increased among 12-month Mutants by 3.70-fold compared to that of 24-month Controls (Figure 5(b)) as compared to its negative control (Figure 5(c)).

3.4. Gene Expression Analysis. mRNA for Insulin was significantly upregulated only at 6 months in Mutants against the data obtained from plasma and tissue insulin, which showed an increase in insulin levels at all the ages (12 months > 6 months > 1 month). The expression levels were, however, comparable in Leans and Controls as reflected by the densitometric analysis (Figure 6(a)).

Pdx-1 homeobox transcription factor required for β-cell functions and regulation of insulin secretion was significantly
Figure 2: Continued.
downregulated in Mutants at both 6 and 12 months with a peak expression seen at 1 month (Figure 6(b)).

Quantitative data generated from RT-PCR further substantiated increased expression of Insulin gene among Mutants, being more pronounced at 6–12 months of age compared with their Lean littermates (values have been normalized against their Controls) (Figure 6(c)). In line with our qRT-PCR data, Pdx-1 expression in Mutants showed down-regulation with age (1 month > 6 months > 12 months) with a peak expression at 1 month. Interestingly, Pdx-1 expression was down regulated in 6–12-month-old Leans when compared with that of their Mutants (age matched/littermates) with a peak expression at 1 month as compared to its Mutant (values have been normalized against their Controls) (Figure 6(d)).

3.5. Primary Islet Cell Cultures

3.5.1. Viability. MTT assay demonstrated an increase in viability during the early phase, that is, 1 month, and declined with age, suggestive of age dependent effects—Mutants (86%, 75%, and 60%), Lean (85%, 80%, and 74%), and Control (98%, 95%, and 85%) corresponding to 1, 6, and 12 months. However, the islet cell integrity was not altered with age and showed >85% intactness, as assessed from the DTZ stained (deep crimson red) islet cell clusters (Figure 8(a) (insights)).

3.5.2. Insulin Secretion Assay. As given in Figure 8(c), Mutants at all the age groups, that is, 1, 6, and 12 months, were hyperinsulinemic as evidenced by an increase in their basal insulin levels similar to our earlier observations of increased insulin levels in both plasma and tissue (Figures 1(c) and 1(j)). However, when Mutant islets were challenged with high glucose concentrations (16.5 mmol/L), insulin secretion was almost absent or was nonresponsive unlike Leans and Controls which elicited a better secretory response under the same conditions. The ratio of basal/challenge secretion, depicting the islet cell functions, was also high in Mutant islets, compared to its Lean and Control counterparts (Figure 8(c)). As a positive control to 12-month Mutants, we have also calculated the ratio of basal/challenge secretion, from the 24-month Control rats (ratio = 1.03), with higher basal insulin secretion levels (24.75 ± 2.86) than when challenged with high glucose (24.13 ± 3.12), and the islets were nonresponsive similar to the findings from 12-month-old Mutant rats (Figure 8(c)).
3.5.3. Ultrastructural Studies (SEM/TEM). SEM data revealed spherical and globular pancreatic β-cells amongst the phenotypes, but fine perforations with ruffles on the islet surface were more prominent with Mutant islets, as Lean and Control islets demonstrated a smooth surface with no such perforations (Figure 8(b)).

On similar lines, TEM photographs showed electron dense spherical secretory granules for insulin among Leans and Controls, while Mutants showed a comparatively less number of the secretory granules with distinct degranulation and vacuolation in the islet region (Figure 8(b)).

3.6. Correlation Analysis. Bivariate 2-tailed correlation analysis of metabolic health measures such as HOMA-IR and QUICKI with other physiological parameters revealed a significant correlation between IR indices-HOMA-IR and QUICKI, with body weight, pancreatic tissue weight, FPG, FPI, plasma and tissue TBARS, tissue insulin levels, islet size, and islet AI at $P < 0.01$. These results have been summarized in Table 1.

4. Discussion
The present study demonstrates for the first time an age dependent (1–12 months) increase in hypertrophy, inflammation, and β-cell dysfunctions with significant degranulation of the insulin secreting cells in the pancreas from Mutants (obesity/IR/HI) which otherwise show distinct features of obesity and IR [7]. These observations are noteworthy in view of the recent reports defining obesity and IR as a state of
Figure 4: Inflammatory stress responses. Immunofluorescence staining of pancreatic sections for inflammatory markers shown by colocalization (yellow) with macrophage marker CD11b (green) and proinflammatory cytokine for TNFα (red) shows more CD11b/TNFα colocalization with Mutant pancreas (a) compared to Lean and Control and comparable with (b) 24 months older in age Control; (c) represents its isotype control. (d and e) represent RFU for CD11b and TNFα, respectively, amongst phenotypes. Mutant pancreas also showed an increase in (f) IL-6, compared to its Lean and Control, and was similar to (g) 24-month Control; (h) represents isotype control and (i) RFU for IL-6 amongst phenotypes. An asterisk (*) represents significance ($P < 0.05$ by ANOVA) compared to Control and ($) indicates significance ($P < 0.05$ by ANOVA) compared to the same phenotype at 1 month.
|                          | Body weights | Pancreas weights | HOMA-IR | QUICKI | FPG | FPI | Plasma TBARS | Tissue TBARS | Tissue insulin | Islet size | Apoptotic index |
|--------------------------|--------------|------------------|---------|--------|-----|-----|--------------|--------------|----------------|------------|------------------|
| **Pearson correlation**  |              |                  |         |        |     |     |              |              |                |            |                  |
| **Sig. (2-tailed)**      |              |                  |         |        |     |     |              |              |                |            |                  |
| **Body weights**         | 1            |                  |         |        |     |     |              |              |                |            |                  |
| **Pancreas weights**     | 0.700**      | 1                |         |        |     |     |              |              |                |            |                  |
| **HOMA-IR**              | 0.500**      | 1                | 1       |        |     |     |              |              |                |            |                  |
| **QUICKI**               | 0.678**      | 0.372**          | 0.765** |        |     |     |              |              | 0.408**        | 1          |                  |
| **FPG**                  | 0.339*       | 0.123            | 0.431** | 0.397** |     |     |              |              |                |            |                  |
| **FPI**                  | 0.884**      | 0.494**          | 0.995** | 0.751** |     |     |              |              | 0.408**        | 1          |                  |
| **Plasma TBARS**         | 0.818**      | 0.837**          | 0.626** | 0.294* | 0.601** | 1   |              |              |                |            |                  |
| **Tissue TBARS**         | 0.917**      | 0.821**          | 0.669** | 0.178  | 0.658** | 0.874** | 1         |              |                |            |                  |
| **Tissue insulin**       | 0.812**      | 0.827**          | 0.710** | 0.221  | 0.702** | 0.778** | 0.800** | 1         |              |            |                  |
| **Islet size**           | 0.765**      | 0.700**          | 0.749** | 0.275* | 0.725** | 0.696** | 0.699** | 0.702** | 1          |            |                  |
| **Apoptotic index**      | 0.924**      | 0.554**          | 0.971** | 0.367** | 0.964** | 0.657** | 0.745** | 0.733** | 0.760** | 1 |                  |

The table shows the correlation analysis between metabolic health parameters and physiological parameters and demonstrates a strong correlation of HOMA-IR and QUICKI with body weights, pancreas weights, plasma and tissue insulin levels, and plasma and tissue TBARS levels (n = 54). The table also shows the correlation analysis for other metabolic and physiological parameters (n = 54). FBG: fasting blood glucose, FPI: fasting plasma insulin, HOMA-IR: homeostasis model of assessment for insulin, QUICKI: quantitative insulin sensitivity check index, TBARS: thiobarbituric acid reacting species.

**Correlation is significant at the 0.01 level (2-tailed).
Correlation is significant at the 0.05 level (2-tailed).
profound inflammation and oxidative stress [24]. Interestingly, the present evidence for an early onset of degenerative-like changes was very much appreciable in Mutants which show features of “kinky tail,” a rare trait [3], overweight (Figures 1(a)-1(b)), tissue hypertrophy/ hyperplasia (Figures 1(g)-1(i)), inflammation (Figure 4), and apoptosis (Figure 5). These changes very much complement the chronic inflammatory conditions and related metabolic disorders [1] well illustrated in this animal model (Table 1). Several etiological factors such as environmental, genetic, and epigenetic factors [1] in addition to IR have been shown to alter the functions of adipose and muscle tissues eventually causing altered glucose homeostasis [9] and thereby impairing islet cell functions and integrity, a phenomenon well noted in T2D [10].

Using cellular, molecular, and morphological approaches, we have been able to demonstrate the coprecipitation of several confounding factors in Mutant pancreas noted by extensive vascularization (Figures 1(g) and 1(h)), interlobular septa with fat accumulation (Figures I(g) and I(h)), increased macrophage infiltration (CD11b) (Figures 4(a)-4(e)), and proinflammatory cytokines (TNFα and IL-6) (Figures 4(a)-4(i)) when compared to its Lean and Control. Inflammation as an intrinsic mechanism to facilitate towards islet dysfunction has been well correlated with frank diabetes and hyperglycemia in TID [27], obese T2D [28], and T2D with IR [28], unlike our present model system demonstrating eu glycemia with obesity/IR [3, 6] suggestive of the preclinical scenario in human subjects [29]. Earlier studies from our institute have shown an altered immune status in the WNIN Mutant rats (WNIN/Ob and WNIN/GR-Ob) in terms of percentages of splenic CD8+ T cytotoxic cells in males and splenic CD3+ T lymphocytes and CD4+ T helper cells in females, respectively, and in response to vaccination [30, 31]. CD11b studied here is a macrophage marker that is highly expressed as a surface marker of activation on resting monocytes along with others such as CD11c and HLADR [32] which correlates with the increased macrophage and T-cell activation among Mutants and with age. This is further confirmed from the observed increased expression of inflammatory cytokines, IL-6 and TNFα, released by activated macrophages. TNFα has been implicated as a key molecule to facilitate insulin-mediated glucose uptake at peripheral tissues [33] and the increased expression of TNF-α (Figures 4(a)-4(e)) could however be partly responsible for the marked increase in macrophage infiltration (Figures 4(a)-4(e)) and IL-6 expression that we have observed from the Mutant pancreas (Figures 4(f)-4(i)). Indeed, TNFα has been reported to upregulate IL-6 in murine pancreatic islets [34] and IL-6 has been shown to be infiltrated in islets both before and during immune infiltration in NOD mice suggesting its pathogenic role, closely correlating to target β-cells [35]. Further, overexpression studies in NOD mice have also demonstrated the interplay of IL-6 with proinflammatory cytokines (e.g., TNFα) leading to β-cell dysfunction [35]. Increased localization of CD11b with a concomitant upregulated expression of downstream inflammatory markers IL-6 and TNFα observed here in the Mutant pancreatic islets unequivocally demonstrates an activated macrophage phenotype in the pancreatic islets/tissue and

Figure 5: Apoptosis (TUNEL assay). Apoptosis detected by TUNEL assay shows red (pseudocolor) nuclei (counterstained with DAPI (blue). Mutants showed an increase in (a) apoptosis as compared to Lean and Control and apoptotic index (b) and it is comparable with 24-month-old Controls; (c) represent its negative control. Quantitatively, AI was significantly higher in (d) Mutants compared to Lean and Control and with age. Mean ± SE (n = 6). An asterisk (*) represents significance (P < 0.05 by ANOVA) compared to Control and ($) indicates significance (P < 0.05 by ANOVA) compared to the same phenotype at 1 month.
Figure 6: Gene expression (semiquantitative and real-time PCR) mRNA levels for (a) Insulin-1 were increased in Mutants with age as compared to their phenotypes. However (b) Pdx-1 expression was downregulated with age (1 > 6 > 12 months). Gel images have been represented for (a) Insulin-1 and (b) Pdx-1. In line with semiquantitative data, mRNA transcripts were upregulated for (c) Insulin-1 in Mutants with age as compared to their phenotypes. In similar lines (d) Pdx-1 expression was downregulated with age (1 > 6 > 12 months). The values have been represented as $2^{-\Delta\Delta CT}$ against Control. Statistical significance (P < 0.05 by ANOVA) has been represented as compared to Control by an asterisk (*) and as compared to younger age by ($$).
Figure 7: Immunolocalization of insulin and Pdx-1. Pdx-1 (red) shows increased nuclear localization in (a) 1-month Mutants followed by (b) 6-month Mutants and (c) 12-month Mutants compared with their Leans and Controls among insulin (green) positive β-cells. The localization was almost similar between 12-month Mutants and (d) older age (24-month) Controls. RFU has been represented (e) amongst phenotypes. Statistical significance ($P < 0.05$ by ANOVA) has been represented compared to Control by an asterisk (*) and compared to younger age by ($$).

(Figure 2(h)), (c) mRNA levels of Insulin (Figures 6(a) and 6(c)), (d) downregulation of Pdx-1 expression (Figures 6(b) and 6(d)), (e) HI (Figure 1(c)), and (f) increase in β-cell size/β-cell volume (Figure 2(i)) [46], advocates for in situ inflammation with Mutants, which probably accounts for β-cell dysfunction. Studies have demonstrated a decreased expression and/or DNA binding activities of MafA and PDX-1 in diabetes and chronic hyperglycemia which present a gradual deterioration of pancreatic β-cell function [47]. Pdx-1 is known to control the expression of two key genes: Insulin and Glut-2 which are required for the integrity and function of islet cells. Pdx-1 is a common transcription factor required for β-cell development, differentiation, function, and pancreatic regeneration. The vulnerability of PDX-1 to the oxidative stress (suppression) has been well demonstrated both in vitro in HIT cells 36 and in vivo in the partially pancreatectomized rats exposed to chronic hyperglycemia [11, 48].

Pancreatic β-cells are constantly exposed to a great demand for insulin production, and ER has been reported to play a critical role towards preserving β-cell functions and differentiation [49, 50]. It is of utmost importance to note that β-cells have weak inherent antioxidant systems compared to other organs in the body making them highly vulnerable to the deleterious effects of oxidative stress [11]. Addressing these issues, we have demonstrated with age an

|   | DAPI | Insulin | Pdx-1 | Merge |
|---|------|---------|-------|-------|
| Control |        |         |       |       |
| Lean    |        |         |       |       |
| Mutant  |        |         |       |       |

- **DAPI**
- **Insulin**
- **Pdx-1**
- **Merge**

(a) (b) (c) (d) (e) (f)
Figure 8: Insulin secretion assay and ultrastructural studies on primary islet cell cultures. (a) Bright field images of primary islet cultures isolated from Mutant, Lean, and Control at 1, 6, and 12 months. Insights show the DTZ stained islets (magnification of 100x). (b) shows the ultrastructural studies of 12-month Mutant phenotypes by scanning (SEM) and (c) transmission electron microscopy (TEM). As shown in the figures Mutants showed less integrity with a ruptured outer collagenous layer (black arrows) and perforations (white arrow heads) (SEM), degranulation of insulin crystals, large less electron dense secretory granules (arrow head), and vacuolation (v) (TEM) compared to their Lean and Control. Insulin secretion measured from 250 islets: (d) basal (5.5 mmol/L glucose), (e) stimulated (16.5 mmol/L glucose), and (f) basal to stimulated insulin secretion, shows impaired insulin secretion with challenge (16.5 mmol/L glucose) from Mutants with age as compared to their Leans and Controls. However, Mutants showed higher basal insulin levels with age.

Increase in RL-77 (ER stress) (Figures 3(b), 3(e), and 3(f)), TBARS (Figures 1(f) and 1(k)), and HSP-104 (Figures 3(a), 3(c), and 3(d)) in these Mutants (compared to their Leans and Controls) with a concomitant increase in expression of stress proteins including ER [51] and HSPs [15, 50, 52]. In similar lines in vitro experiments, using insulinoma cells [53] and primary islet cells [53] also demonstrates pancreatic β-cell dysregulation or death [54] with upregulation of UPR genes. As shown in Figure 5, age dependent degenerative changes and apoptosis (TUNEL assay) seem to have played an important role in increased β-cell vacuolation (12 months > 6 months > 1 month) in Mutants (Figures 1(g) and 1(h)). Interestingly, the accelerated aging process has been a well-documented phenomenon in these Mutants with their average life span shortened to 1.5 yrs compared to 2.5–3 years seen in Controls and Leans [3] and the phenomenal increase in episodes of cataract [6, 55], cancers [6], infertility [56], and immune dysfunction [30] playing a critical role to shorten their lifespan as given in Figure 9.

To obtain further insights underlying altered pancreatic milieu, we next examined functional responses (with age) and ultrastructural changes (only 12 months) using primary islet cell cultures isolated from these phenotypes. Mutant islets depicted inflammatory milieu evidenced by their
nonresponsiveness to high glucose challenge (16.5 mmol/L) >6 and 12 months (Figure 8(c)) [57]. The perturbations noted with functional responses of islets to glucose challenge could be a multifactorial effect and can be attributed to a reduced threshold of the β-cells under chronic conditions [58] and islet hypertrophy [59] or can be due to the functional loss of insulin receptor [60], hypertriglyceridermia [61], inflammation [6], hyperleptinemia [62], oxidative stress [63], and IR [29]. Higher basal insulin levels (5.5 mmol/L glucose) observed with Mutant islets at all ages (1/6/12 months) (Figure 8(c)) could probably be noted as a compensatory response initiated by β-cells resulting in HI [45] or by insulin hypersecretion under substimulatory conditions [61, 62].

Ultrastructural analysis of the primary islet cells (12 months) revealed significant inflammatory/apoptotic responses in Mutants evidenced by a disrupted outer collagenous layer (SEM) and this data was complemented with TEM findings for increased islet cell degranulation evidenced in Mutant islets (Figure 8(b)). Interestingly, data generated from model systems such as Zucker fatty rats [64] and sand rats [65] have advocated for an increased macrophage accumulation [66] and IL-6 expression [66] in β-cells themselves [38], contributing to islet cell impairments suggestive of a prediabetic state [51]. Systemic elevation of IL-6 cytokine in obesity has been identified as the risk/predictive factor for development of T2D [35] akin to our present observations. Further, in vitro studies [35] show that increased expression of IL-6 renders inhibition of glucose-stimulated insulin secretion [35], albeit that results have not been consistent.

Interestingly we have attempted here to integrate and correlate metabolic health measures of HOMA-IR and QUICKI amongst the phenotypes (Table I) with other measures such as body weight, fasting plasma glucose, fasting plasma insulin, pancreatic tissue TBARS, islet size, and islet apoptotic index. to arrive at a significant correlation of metabolic insult to be associated with the Mutant trait, as compared with its Lean and Control.

5. Conclusions

Our findings in situ and in vitro authenticate the use of WNIN/Ob Mutant model as an optimal system for studying MS (obesity/IR/T2D) and its complications which are increasing worldwide at an alarming rate. These findings pave the way to explore the efficacy and feasibility of using these mutant rats as a valuable resource (model systems) in the management of obesity and metabolic syndrome.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors’ Contribution

Dr. Vijayalakshmi Venkatesan designed the experiment and prepared the paper. Mrs. Soundarya Madhira carried out the in situ characterizations and prepared the draft. Mr. Venkata Malakapalli carried out gene expression studies. Mrs. Maniprabha Chalasani worked on the immunohistochemistry for all the markers given in the paper. Dr. Sarfaraz Nawaz prepared the islet cell cultures and prepared samples for ultrastructural analysis. Dr. Vasudevan Sheshadri contributed the endoplasmic reticulum component of the paper, including the antibody contribution. Dr. Venkaiah Kodavalla gave the entire feedback on statistical applications to the study. Dr. Ramesh Bhonde contributed his expertise towards islet cell virology, including inflammation. Dr. Giridharan Nappanveetil was responsible for the development of WNIN mutant obese rats and collaborated in the present study.

Acknowledgments

The authors wish to thank the Director of the National Institute of Nutrition, Indian Council of Medical Research (Flagship Project), Hyderabad, for extending grant support to execute this work. They also thank Dr. NV Giridharan and
Dr. P Suresh, the former and present, respectively, person in charge of NCLAS, for extending support to carry out the animal experiments. They deeply acknowledge help extended by Dr. P Uday Kumar (Pathology Head) and his team for providing them with tissue sections.

References

[1] M. Qatanani and M. A. Lazar, “Mechanisms of obesity-associated insulin resistance: many choices on the menu,” Genes and Development, vol. 21, no. 12, pp. 1443–1455, 2007.
[2] W. T. Cefalu, “Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition,” ILAR Journal, vol. 47, no. 3, pp. 186–198, 2006.
[3] N. V. Giridharan, “Animal models of obesity and their usefulness in molecular approach to obesity,” Indian Journal of Medical Research, vol. 108, pp. 225–242, 1998.
[4] R. R. Kalashikam, K. K. Battula, V. Kirlampalli, J. M. Friedman, and G. Nappanveetil, “Obese locus in WNIN/obese rat maps on chromosome 5 upstream of leptin receptor,” PLoS ONE, vol. 8, no. 10, Article ID e77679, 2013.
[5] N. V. Giridharan, P. Sailaja, and N. Harishankar, “A new obese rat model to study obesity and cardiovascular risks,” Proceedings of CMJ Journal, vol. 96, 2010.
[6] N. Harishankar, P. U. Kumar, B. Sesikeran, and N. Giridharan, “Obesity associated pathophysiological & histological changes in WNIN obese mutant rats,” Indian Journal of Medical Research, vol. 134, no. 9, pp. 330–340, 2011.
[7] S. L. Madhira, G. Nappanveetil, V. Kodavalla, and V. Venkatesan, “Comparison of adipocyte-specific gene expression from WNIN/Ob mutant obese rats, lean control, and parental control,” Molecular and Cellular Biochemistry, vol. 357, pp. 217–225, 2011.
[8] S. L. Madhira, S. S. Challa, M. Chalasani et al., “Promise(s) of mesenchymal stem cells as an in vitro model system to depict pre-diabetic/diabetic milieu in WNIN/GR-Ob mutant rats,” PLoS ONE, vol. 7, no. 10, Article ID e48061, 2012.
[9] G. Kewalramani, P. J. Bilan, and A. Klip, “Muscle insulin resistance: assault by lipids, cytokines and local macrophages,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 4, pp. 382–390, 2010.
[10] C. Wang, Y. Guan, and J. Yang, “Cytokines in the progression of pancreatic β-cell dysfunction,” International Journal of Endocrinology, vol. 2010, Article ID 515136, 10 pages, 2010.
[11] S. G. Kiran, R. K. Dorisety, M. R. Umran et al., “Pyridoxal 5′ phosphate protects islets against streptozotocin-induced beta-cell dysfunction- in vitro and in vivo,” Experimental Biology and Medicine, vol. 236, no. 4, pp. 456–465, 2011.
[12] R. Kikkawa, “Chronic complications in diabetes mellitus,” British Journal of Nutrition, vol. 84, no. 2, pp. S183–S185, 2000.
[13] T. Mitsuhashi, K. Hibi, M. Kosuge et al., “Relation between hyperinsulinemia and nonculprit plaque characteristics in nondiabetic patients with acute coronary syndromes,” JACC: Cardiovascular Imaging, vol. 4, no. 4, pp. 392–401, 2011.
[14] V. Venkatesan, M. Chalsani, S. S. Nawar, R. R. Bhonde, S. S. Challa, and G. Nappanveetil, “Optimization of condition(s) towards establishment of primary islet cell cultures from WNIN/Ob mutant rat,” Cytotechnology, vol. 64, no. 2, pp. 139–144, 2012.
[15] A. Chairmandurai, S. Kanappa, K. Vadrevu, U. Putcha, and V. Venkatesan, “Recombinant human epidermal growth factor alleviates gastric antral ulcer induced by naproxen: a non-steroidal anti inflammatory drug,” Gastroenterology Research, vol. 3, pp. 1918–2813, 2010.
[16] R. K. Dorisetty, S. G. Kiran, M. R. Umran, S. Boindala, R. R. Bhonde, and V. Venkatesan, “Immunolocalization of nestin in pancreatic tissue of mice at different ages,” World Journal of Gastroenterology, vol. 14, no. 46, pp. 7112–7116, 2008.
[17] G. Gobe, “Identification of apoptosis in kidney tissue sections,” Methods in Molecular Biology, vol. 466, pp. 175–192, 2009.
[18] D. T. Finegood, M. D. McArthur, D. Kojwang et al., “β-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death,” Diabetes, vol. 50, no. 5, pp. 1021–1029, 2001.
[19] K. Mishima, A. P. Mazar, A. Gown et al., “A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits globlastoma growth and angiogenesis in vivo in combination with cisplatin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8484–8489, 2000.
[20] A.-A. Dussault and M. Poulion, “Rapid and simple comparison of messenger RNA levels using real-time PCR,” Biological Procedures Online, vol. 8, no. 1, pp. 1–10, 2006.
[21] M. M. Amoli, R. Moosavizadeh, and B. Larjani, “Optimizing conditions for rat pancreatic islets isolation,” Cytotechnology, vol. 48, no. 1–3, pp. 75–78, 2005.
[22] Y.-F. Cui, M. Ma, G.-Y. Wang, D.-E. Han, B. Vollmar, and D. D. Menger, “Prevention of core cell damage in isolated islets of Langerhans by low temperature preconditioning,” World Journal of Gastroenterology, vol. 11, no. 4, pp. 545–550, 2005.
[23] S. S. Challa, G. S. Kiran, R. R. Bhonde, and V. Venkatesan, “Enhanced neogenic potential of Panc-1 cells supplemented with human umbilical cord blood serum-An alternative to FCS,” Tissue and Cell, vol. 43, no. 4, pp. 266–270, 2011.
[24] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003.
[25] L. Singotamu and P. M. Chary, “Scanning electron microscope studies on genetically modified (GM) crops–G.M. cotton fiber (Gossypium herbaceum),” Scanning, vol. 27, no. 3, pp. 160–161, 2005.
[26] V. Vijayalakshmi and P. D. Gupta, “Role of transglutaminase in keratinization of vaginal epithelial cells in oestrous cycling rats,” Biochemistry and Molecular Biology International, vol. 43, no. 5, pp. 1041–1049, 1997.
[27] M. Cnop, N. Welsh, J.-C. Jonas, A. Jorns, S. Lenzen, and D. L. Eizirik, “Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes; many differences, few similarities,” Diabetes, vol. 54, no. 2, pp. S97–S107, 2005.
[28] J. A. Ehses, A. Perren, E. Eppler et al., “Increased number of islet-associated macrophages in type 2 diabetes,” Diabetes, vol. 56, no. 9, pp. 2356–2370, 2007.
[29] C.-H. Hsieh, Y.-I. Hung, C.-Z. Wu et al., “Insulin resistance & secretion in subjects with normal fasting plasma glucose,” Indian Journal of Medical Research, vol. 124, pp. 527–534, 2006.
[30] P. Bandaru, H. Rajkumar, and G. Nappanveetil, “Altered or impaired immune response upon vaccination in WNIN/Ob rats,” Vaccine, vol. 29, no. 16, pp. 3038–3042, 2011.
[31] P. Bandaru, H. Rajkumar, and G. Nappanveetil, “The impact of obesity on immune response to infection and vaccine: an insight into plausible mechanisms,” Endocrinology & Metabolic Syndrome, vol. 2, p. 113, 2013.
K. E. Wellen and G. S. Hotamisligil, "Obesity-induced inflammation, "Clinical and Experimental Immunology, vol. 134, no. 3, pp. 464–469, 2003.

L. Rui, V. Aguirre, J. K. Kim et al., "Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways," Journal of Clinical Investigation, vol. 107, no. 2, pp. 181–189, 2001.

M. Chentouf, G. Dubois, C. Jahannaut et al., "Excessive food intake, obesity and inflammation process in Zucker fa/fa rat pancreatic islets," PLoS ONE, vol. 6, no. 8, Article ID e22954, 2011.

O. P. Kristiansen and T. Mandrup-Poulsen, "Interleukin-6 and diabetes: the good, the bad, or the indifferent?" Diabetes, vol. 54, no. 2, pp. S14–S124, 2005.

D. C. Nieman, S. L. Nehlsen-Cannarella, D. A. Henson et al., "Immune response to obesity and moderate weight loss," International Journal of Obesity, vol. 20, no. 4, pp. 353–360, 1996.

D. O’Shea, T. J. Cawood, C. O’Farrelly, and L. Lynch, "Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke," PLoS ONE, vol. 5, no.1, Article ID e6860, 2010.

J.-P. Bastard, M. Maachi, C. Lagathu et al., "Recent advances in the relationship between obesity, inflammation, and insulin resistance," European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006.

C. Procaccini, E. Jirillo, and G. Matarrese, "Leptin as an immunomodulator," Molecular Aspects of Medicine, vol. 33, no. 1, pp. 35–45, 2012.

P. Bandaru, H. Rajkumar, V. P. Upadrasta, and G. Nannapanveelti, "Role of leptin in immune dysfunction in WNN obese rats," Endocrinology & Metabolic Syndrome, vol. 2, p. 116, 2013.

V. de Rosa, C. Procaccini, G. Calì et al., "A key role of leptin in the control of regulatory T cell proliferation," Immunity, vol. 26, no. 2, pp. 241–255, 2007.

H. K. Vincent and A. G. Taylor, "Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans," International Journal of Obesity, vol. 30, no. 3, pp. 400–418, 2006.

P. A. Tataranni and E. Ortega, "A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?" Diabetes, vol. 54, no. 4, pp. 917–927, 2005.

K. E. Wellen and G. S. Hotamisligil, "Obesity-induced inflammatory changes in adipose tissue," Journal of Clinical Investigation, vol. 112, no.12, pp. 1785–1788, 2003.

Y. Saisho, A. E. Butler, E. Manesco, D. Elashoff, R. A. Rizza, and P. C. Butler, "β-cell mass and turnover in humans: effects of obesity and aging," Diabetes Care, vol. 36, pp. 111–117, 2013.

D. A. Nugent, D. M. Smith, and H. B. Jones, "A review of islet of Langerhans degeneration in rodent models of type 2 diabetes," Toxicologic Pathology, vol. 36, no. 4, pp. 529–551, 2008.

H. Kaneto, T.-A. Matsuo, S. Kawashima et al., "Role of MafA in pancreatic β-cells," Advanced Drug Delivery Reviews, vol. 61, no. 7–8, pp. 489–496, 2009.

D. Kawamori, Y. Kajimoto, H. Kaneto et al., "Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH2-terminal kinase," Diabetes, vol. 52, no. 12, pp. 2896–2904, 2003.

K. L. Lipson, S. G. Fonseca, S. Ishigaki et al., "Regulation of insulin biosynthesis in pancreatic beta cells by an endoplasmic reticulum-resident protein kinase IRE1," Cell Metabolism, vol. 4, no. 3, pp. 245–254, 2006.

R. J. Kaufman, S. H. Back, B. Song, J. Han, and J. Hassler, "The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β-cells," Diabetes, Obesity and Metabolism, vol. 12, no. 2, pp. 99–107, 2010.

U. Özcan, Q. Cao, E. Yilmaz et al., "Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes," Science, vol. 306, no. 5695, pp. 457–461, 2004.

S. Thanumalayan, M. Laxmi Narasu, and V. Venkatesan, "Down regulation of suppressor of potassium transport defect 3 (SKD3) in testis of nonobese diabetic (NOD) mice," Indian Journal of Veterinary Pathology, vol. 32, pp. 242–245, 2008.

D. A. Cunha, P. Hekerman, L. Ladrére et al., "Initiation and execution of lipotoxic ER stress in pancreatic β-cells," Journal of Cell Science, vol. 121, no. 4, pp. 2308–2318, 2008.

W. Quan, Y.-M. Lim, and M.-S. Lee, "Role of autophagy in diabetes and endoplasmic reticulum stress of pancreatic β-cells," Experimental and Molecular Medicine, vol. 44, no. 2, pp. 81–88, 2012.

G. B. Reddy, V. Vasireddy, M. N. A. Mandal et al., "A novel rat model with obesity-associated retinal degeneration," Investigative Ophthalmology and Visual Science, vol. 50, no. 7, pp. 3456–3463, 2009.

N. Harishankar, R. Ravinder, K. M. Nair, and N. Giridharan, "Infertility in WNN obese mutant rats-causes?" ISRN Endocrinol, vol. 2011, Article ID 863403, 7 pages, 2011.

M. Y. Donath, M. Böni-Schnetzler, H. Ellingsgaard, and J. A. Ehles, "Islet inflammation impairs the pancreatic B-cell II in type 2 diabetes," Physiology, vol. 24, no. 6, pp. 325–331, 2009.

N.-G. Chen, T. M. Tassava, and D. R. Romso, "Threshold for glucose-stimulated insulin secretion in pancreatic islets of genetically obese (ob/ob) mice is abnormally low," Journal of Nutrition, vol. 123, no. 9, pp. 1567–1574, 1993.

K. Kaneko, K. Ueki, N. Takahashi et al., "Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms," Cell Metabolism, vol. 12, no. 6, pp. 619–632, 2010.

Y.-L. Ding, Y.-H. Wang, W. Huang et al., "Glucose intolerance and decreased early insulin response in mice with severe hypertriglycerideremia," Experimental Biology and Medicine, vol. 235, no. 1, pp. 40–46, 2010.

H.-E. Kim, S.-E. Choi, S.-J. Lee et al, "Tumour necrosis factor-α-induced glucose-stimulated insulin secretion inhibition in INS-1 cells is ascribed to a reduction of the glucose-stimulated Ca2+ influx," Journal of Endocrinology, vol. 198, no. 3, pp. 549–560, 2008.

J. Seufert, "Leptin Effects on Pancreatic β-Cell Gene Expression and Function," Diabetes, vol. 53, no. 1, pp. SI52–SI58, 2004.

L. P. Roma, S. M. Pascal, J. Duprez, and J. C. Jonas, "Mitochondrial oxidative stress contributes differently to rat pancreatic islet cell apoptosis and insulin secretory defects after prolonged culture in a low non-stimulating glucose concentration," Diabetologia, vol. 55, pp. 2226–2237, 2012.

R. Alemzadeh and K. M. Tushaus, "Modulation of adipoinflammatory axis in prediabetic Zucker diabetic fatty rats by diazoxide," Endocrinology, vol. 145, no. 12, pp. 5476–5484, 2004.
[65] G. Üçkaya, P. Delagrange, A. Chavanieu et al., “Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue,” *Journal of Endocrinology*, vol. 184, no. 3, pp. 505–513, 2005.

[66] M. Y. Donath, M. Böni-Schuetzler, H. Ellingsgaard, P. A. Halban, and J. A. Ehses, “Cytokine production by islets in health and diabetes: cellular origin, regulation and function,” *Trends in Endocrinology and Metabolism*, vol. 21, no. 5, pp. 261–267, 2010.